Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505(b)(2) NDA for approval to market the high-dose aspirin product.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.